15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Biofrontera Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $3.00 to $3.00, so the covering firms are broadly aligned. The average target of $3.00 sits 99% above the current $1.50. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.31 next quarter toward $0.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Biofrontera Inc.
As of Aug, 1 of 1 firms rate BFRI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BFRI EPS & revenue forecast
EPS · NEXT QUARTER
$0.31
Range $0.31 – $0.31 · 1 analysts · -38% YoY
Next period, 1 analysts expect Biofrontera Inc to earn $0.31 a share (range $0.31 – $0.31), versus $0.50 a year earlier. Full-year consensus is $-0.18, growing to $0.43 the year after.
REVENUE · NEXT QUARTER
$15.8M
Range $15.8M – $15.8M · 1 analysts · -8% YoY
Revenue is expected to reach $15.8M (range $15.8M – $15.8M), -7.6% year-over-year. Full-year consensus is $46.1M, rising to $53.5M next year.
Top analysts covering Biofrontera Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BFRI.
#1
Bruce Jackson
Benchmark · Rank #366
Buy
$3.00+99.3% to target
Overall win rate
36%
+ Follow
#2
Jonathan Aschoff
Roth MKM · Rank #444
Buy
$9.00+498.0% to target
Overall win rate
28%
+ Follow
BFRI stock forecast FAQ
What is BFRI's average 12-month price target?+
The 1 analysts with a live target average $3.00 for Biofrontera Inc over the next 12 months, ranging from a $3.00 high to a $3.00 low.
Is BFRI stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover BFRI?+
1 analysts have an active rating on Biofrontera Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering BFRI?+
Among analysts who currently cover BFRI, Bruce Jackson of Benchmark has the strongest overall Quantellect track record (Rank #366). Their current call is Buy with a $3.00 target.
What is Biofrontera Inc's projected EPS for next quarter?+
The consensus estimate is $0.31 per share (range $0.31 – $0.31) across 1 analysts. Full-year EPS is projected at $-0.18, rising to $0.43 the following year.
How much revenue is Biofrontera Inc expected to report next quarter?+
Consensus revenue is $15.8M (range $15.8M – $15.8M). Full-year revenue is projected at $46.1M, growing to $53.5M next year.
Have analysts been upgrading or downgrading BFRI lately?+
As of Aug, 1 of 1 firms rate BFRI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BFRI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
